Engine Biosciences
Focus: Engine Biosciences is an early-stage AI & genomics-focused biotech founded in 2023, headquartered in Redwood City, CA, with a current portfolio dominated by generic and branded post-LOE assets. The company operates across five therapeutic areas (Neurology, Infectious Diseases, Cardiovascular, Oncology, Nephrology) but lacks disclosed employee count and funding details.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Open Jobs
0
About Engine Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Engine Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Engine Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
1 in 5yr
FLOLIPID
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$23M Part DDeclining
Post-LOE
Statin ANDA generating 69% of company revenue, indicating reliance on mature, commoditized cardiology asset with limited growth runway.
Help build intelligence for Engine Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.